Towards the clinical implementation of pharmacogenetics in bipolar disorder

Naji C Salloum1,2, Michael J McCarthy1,2, Susan G Leckband1,2 and John R Kelsoe1,2,3*

Abstract

Background: Bipolar disorder (BD) is a psychiatric illness defined by pathological alterations between the mood states of mania and depression, causing disability, imposing healthcare costs and elevating the risk of suicide. Although effective treatments for BD exist, variability in outcomes leads to a large number of treatment failures, typically followed by a trial and error process of medication switches that can take years. Pharmacogenetic testing (PGT), by tailoring drug choice to an individual, may personalize and expedite treatment so as to identify more rapidly medications well suited to individual BD patients.

Discussion: A number of associations have been made in BD between medication response phenotypes and specific genetic markers. However, to date clinical adoption of PGT has been limited, often citing questions that must be answered before it can be widely utilized. These include: What are the requirements of supporting evidence? How large is a clinically relevant effect? What degree of specificity and sensitivity are required? Does a given marker influence decision making and have clinical utility? In many cases, the answers to these questions remain unknown, and ultimately, the question of whether PGT is valid and useful must be determined empirically. Towards this aim, we have reviewed the literature and selected drug-genotype associations with the strongest evidence for utility in BD.

Summary: Based upon these findings, we propose a preliminary panel for use in PGT, and a method by which the results of a PGT panel can be integrated for clinical interpretation. Finally, we argue that based on the sufficiency of accumulated evidence, PGT implementation studies are now warranted. We propose and discuss the design for a randomized clinical trial to test the use of PGT in the treatment of BD.

Keywords: Bipolar Disorder, Pharmacogenomics, Lithium, Antidepressants, Antipsychotics

Background

Bipolar disorder (BD) is a psychiatric illness that affects 3% to 5% of the population [1], and is characterized by recurring and severe changes in mood, leading to significant impairment, and increased risk for suicide. The estimated direct and indirect costs of BD in the US are estimated at $15B [2]. Mood stabilizers are considered the treatment of choice for managing BD. However, evidenced-based treatment guidelines include a wide range of medications, such as antipsychotics, antidepressants, anxiolytics and multi-drug combinations [3,4].

Despite the help of guidelines, psychiatrists face tremendous challenges in treating BD. First, the presentation of BD is heterogeneous, and the diagnosis of BD is often difficult. Psychiatric co-morbidity is common, and the typical patient with BD is misdiagnosed an average of four times [5]. After the diagnosis is established, treatment response is often inadequate, and the rate of remission is poor, particularly among those in the depressive phase [6]. Finally, many drugs are poorly tolerated, and unwanted medication side effects are common. Therefore, while there are broadly accepted best practices for treating BD, their application yields variable, and often unacceptable, outcomes, leaving many patients to suffer prolonged and unsuccessful drug trials before responding to treatment.

A challenge in treating BD is heterogeneity among patient responses. The same drug may have different outcomes in two otherwise similar BD patients, successfully...
treating one, but necessitating a search for an alternative treatment in the other. For this reason, a typical course of treatment is extensive, consisting of serial medication trials until an effective drug or drug combination is identified. Variability in treatment responses may be related to differences in illness pathophysiology and drug metabolism, both factors thought to be influenced by an individual’s genetic background. Therefore, understanding the relationship between genetic factors and treatment response may allow for the development of objective pharmacogenetic tests (PGT) to guide the physician rationally and rapidly towards effective drug treatments for BD.

Recently, many genetic variants have been associated with response-related psychiatric phenotypes, including many in BD. While the strength of this evidence varies, some are now considered reliable. Despite this progress, implementation of this knowledge in the clinic has been limited. It remains unclear if association to response will necessarily translate into improved outcomes, and there has been a reluctance to apply these findings clinically. Other medical disciplines have increasingly demonstrated the utility of personalized medicine [7] with PGT showing advantages in warfarin dosing [8], thiopurine myelosuppression in leukemia [9,10] and abacavir hypersensitivity in HIV [11,12]. However, these fields are experiencing similar inertia, even in cases where the supporting evidence is strong [13].

Questions have been raised in the psychiatric literature regarding the appropriateness of implementing PGT in the clinic, most of which remain unanswered [14]. However, unlike genetic association studies which cannot address clinical utility, implementation studies may provide empirical answers to some of these pertinent issues [Box 1]. Hence, they are urgently needed. In this opinion, we conclude that a few PGT markers, while perhaps not perfect are sufficiently well-established to advocate for research into their implementation to determine if they have clinical value. A preliminary path forward and discussion of the anticipated benefits and obstacles is presented.

**Discussion**

**Pharmacogenetic association studies**

A large number of genetic markers have been associated with Psychotropic response in psychiatry, including many relevant to BD. A number of reviews have been published in recent years [14,15], focused primarily on lithium. However, many drugs used to treat major depression (MDD) or schizophrenia (SCZ) are also effective in BD. Therefore, in organizing this opinion around implementation, we have broadened the scope of PGT in BD to consider these options in addition to lithium. PubMed and the PharmGKB [16] database were searched for pharmacogenetic reports for lithium, anti-seizure drugs, antipsychotics and antidepressants. We then devised criteria to rank these results based on strength of evidence and clinical utility. In doing so, we focused on variants that have been independently replicated in large cohorts. In some cases, the studies were performed in MDD or SCZ. We developed standardized criteria by which genetic markers were assessed. Those categorized as evidence Level 1 were replicated at least once with a P-value of <0.05 after correction for multiple comparisons, in a total population of ≥500 cases of similar ethnicity. Level 2 evidence required replication with P-values <0.05 after correction and at least one population of 100 to 499. Studies with P-values <0.05, but without replication, or in samples <100 were categorized as Level 3. Our search yielded a set of 16 genetic markers that were classified as Level 1 (Table 1). We also included a small number of variants that were compelling candidates based upon convergent animal or pre-clinical studies that met the threshold for Level 2 evidence. Each genotype-drug association is discussed below.

**Pharmacodynamics**

**Lithium response**

Lithium is the most widely used mood stabilizer, greatly decreasing suicide risk and BD symptoms during acute mania, depression and maintenance [17,18]. Clinical
features have been associated with lithium response [19,20], leading some to argue that lithium responsive BD is a distinct illness subtype that can be defined in part by its sensitivity to the drug [21]. However, in a long term prospective study [22], while lithium response was identified as an enduring trait, the classical clinical profile failed to discriminate lithium responders from non-responders. For this reason, efforts have been directed towards pharmacogenetic approaches predicting lithium response. Table 2 summarizes some of the genetic markers reported to be associated to mood stabilizer response.

**BDNF and NTRK2**

Brain-derived neurotrophic factor (BDNF), plays a crucial role in neuronal survival, differentiation and plasticity in the brain [23-25]. BDNF binds to the TrkB receptor, the protein product of *NTRK2*. The BDNF/TrkB signaling pathway is involved in a wide range of intracellular signaling cascades [26] and is thought to play an important role in mediating the therapeutic effects of lithium [27,28]. Past evidence has implicated BDNF in the pathogenesis of BD [29-31], and the BDNFVal66Met polymorphism (rs6265) has been associated with lithium response, whereby carriers of the Met allele had better treatment outcomes [32,33]. The lithium response association with BDNF was recently replicated in a sample of Chinese patients with BD [34], but others have failed to replicate the result [35]. *NTRK2* polymorphisms have been implicated as genetic factors underlying BD in a genomewide association study (GWAS) [36] and associated with lithium response in two independent studies. In the first, two SNPs in *NTRK2* were associated with response specifically in patients with euphoric mania [37]. This association has been subsequently replicated in an independent prospective trial [38]. More recently, another independent study again implicated *NTRK2*, using a different variant [39]. However, not all studies have replicated the *NTRK2* association with lithium response [32]. Different variants in *NTRK2* have been associated with risk for suicide attempts, which is particularly interesting in the light of lithium’s known anti-suicide properties [40].

**CREB**

The cAMP response element-binding protein (CREB1) is a transcription factor that plays important roles in neuroplasticity, cell survival and neuronal modulation by lithium and antidepressants [41-43]. An association between variants in CREB1 and lithium response was reported in a prospective association study conducted on a sample of 258 subjects followed over three years, in which the BD subjects were treated with lithium monotherapy [44]. Of interest, independent CREB1 haplotypes have been associated with selective serotonin receptor inhibitor (SSRI) remission [45], emergent suicidal ideation during SSRI treatment [46] and treatment resistant depression [47], features previously linked to latent bipolarity among depressed subjects.

**GRIA2, ODZ4/TENM4**

In a GWAS of lithium response conducted using subjects from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), five SNPs showed association
with $P$ values of $<5 \times 10^{-4}$ and were independently replicated in a cohort of 359 BD patients. Among these was a variant in GRIA2, a glutamate receptor subunit gene [48]. Glutamate has been strongly implicated in the pathogenesis of BD, and GRIA2 was previously shown to be regulated by lithium in hippocampal neurons [49]. ODZ4 (also named TENM4), has been associated with BD susceptibility in the largest published GWAS to date and was also found to be associated with lithium response [50,51].

**GSK3B**

Glycogen synthase kinase 3β (GSK3B), is an enzyme involved in neuronal development and survival, and is inhibited by lithium [52,53]. A pharmacogenetic study of 88 BD patients identified a functional SNP associated with lithium response in the GSK3B promoter [54]. Similar results were obtained in a cohort of 138 Taiwanese BD subjects [55] and a mixed cohort of BD/MDD receiving augmentation of antidepressants with lithium [56]. However, other studies have failed to detect a similar association [57,58].

**Carbamazepine response**

The anticonvulsant carbamazepine (CBZ) is a mainstay of treatment in BD patients [59,60]; however, no pharmacogenetic studies to date have evaluated response to carbamazepine. Clinical features associated with CBZ response include those with BPII disorder, dysphoric mania, comorbid substance abuse, mood incongruent delusions, negative family history of BD in first-degree relatives, and in those not tolerant to other treatments due to side effects (for example, weight gain, tremor, diabetes insipidus, or polycystic ovarian syndrome) [61].

There has been a strong association reported between the HLA-B*1502 haplotype and the severe life-threatening cutaneous drug reactions, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) [62]. Two studies conducted on Han Chinese patients reported that HLA-B*1502 was present in 100% (44/44) and 98.3% (59/60) of CBZ-induced SJS patients in contrast to 3% (3/101) and 4.2% (6/144) of CBZ-tolerant patients [63,64]. While the risk-associated haplotype is found in 5% to 15% of Asians, clinical guidelines in some healthcare institutions suggest avoiding carbamazepine in all patients of Asian background, thereby potentially depriving the majority of patients in this racial group a proven treatment for BD. Hence, the adaptation of PGT for HLA-B has a huge potential for impact in this group and HLA-B PGT for carbamazepine treatment is now recommended by the Clinical Pharmacogenetics Implementation Consortium (CPIC) [65].

**Valproic acid response**

Relatively little work has been done on the pharmacogenetic response to the anticonvulsant mood stabilizer, valproic acid, and no valproic acid study meets the requirements for inclusion in our implementation list. However, valproic acid is a first line treatment for BD, and its omission constitutes an important gap. Valproic acid pharmacogenetics is likely to be a priority for future research.

**Antipsychotic response**

Antipsychotics are commonly used in BD, both as a first-line treatment in acute mania [66] and depression [67]. However, psychiatrists are increasingly reluctant to use them due to their unfavorable long-term side effect profile, especially weight gain [68]. In addition to metabolic problems, the risk of extra-pyramidal side effects (EPS) associated with second generation antipsychotics is estimated to be 13% to 17% and remains a concern.

Because the majority of the pharmacogenetic studies of antipsychotics have been done with SCZ patients, it requires extrapolation to BD. For this reason, caution is required in interpreting these results. However, many of these data likely apply to BD. First, there is substantial symptom overlap and shared genetic risk between SCZ and BD [50,69], suggesting that underlying illness mechanisms are shared. Moreover, because side effects such as weight gain are assumed to be due to ‘off target’ effects, side effect mechanisms are likely similar across disorders. To be sure, research extending PGT of antipsychotics to BD is required, not only with regard to psychotic symptoms, but also with respect to mood. Genetic variants reported to be associated with antipsychotic response are listed in Table 3.

**DRD2/ANKK1**

The D2 dopamine receptor encoded from DRD2 is the primary target of most antipsychotic medications [70,71]. The -141C insertion/deletion polymorphism located in the DRD2 promoter, has been shown to have a functional effect on expression and has been studied on several occasions with respect to antipsychotic outcomes. In a meta-analysis of 687 SCZ patients from six studies, the -141C variant demonstrated an association with favorable antipsychotic response (>50% reduction in symptoms) at eight weeks [72]. The ankyrin repeat and kinase domain containing 1 gene (ANKK1) is located 10 kb from DRD2 [73], and has been associated with tardive dyskinesia (TD). In a meta-analysis of 1,256 SCZ subjects from six studies, ANKK1 genotype was associated with TD, with odds ratios of 1.30 to 1.50 [74]. A decrease in DRD2 expression was also associated with a risk conferring allele [75,76], perhaps explaining the effect of ANKK1 genotype on TD risk [77].

**HTR2A**

Many antipsychotic drugs alter serotonin signaling by blocking 5HT2A receptors, encoded by HTR2A [78]. Several studies demonstrated a less favorable response
to olanzapine and clozapine among carriers of the rare functional promoter variant, A-1438G in HTR2A [79-81].

**HTR2C**

In attempts to identify genetic vulnerability to antipsychotic induced weight gain and metabolic syndrome, HTR2C, encoding the 5-HT2C receptor, has yielded the most reliable associations. A meta-analysis of eight studies showed a significant association of C759T HTR2C SNP, with a lower risk of weight gain with antipsychotics [82]. Similarly, ten independent studies on schizophrenic patients have shown a significant association between the C-allele of the same SNP and higher risk of antipsychotic-induced weight gain [77].

**MC4R**

MC4R, one of the most important genes associated with weight gain and increased risk for obesity [83,84], has been shown to play a role in the modulation of food intake and energy homeostasis [85,86]. It has also been associated with atypical antipsychotics-induced weight gain in a GWAS conducted on 139 pediatric subjects, with replication in three additional cohorts [87]. Another SNP, previously associated with weight gain [83] yielded similar results [88].

**Antidepressant response**

Although controversial [89], SSRIs are widely used in conjunction with mood stabilizers or antipsychotics for depression in BD, appearing in evidence-based psychopharmacology guidelines [90,91]. However, because of their questionable efficacy and potential for inducing mania, there is a need to identify genetic variants associated with response and adverse events, such as manic switch and rapid cycling. SSRI response has been primarily studied in MDD or mixed BD/MDD samples. Therefore, our extrapolation from MDD to BD may have important caveats in the use of these markers. Table 4 summarizes genes associated with antidepressant response.

**SLC6A4 (5-HTTLPR)**

The 5-HTTLPR is a 44 bp insertion/deletion within the promoter of SLC6A4, the gene encoding the serotonin transporter [92]. Transcriptional activity among carriers of the short allele (S) has been shown to be lower compared to carriers of the long allele (L) [92,93]. Fifteen studies encompassing 1,435 MDD and BD patients were analyzed for association with SSRI response [94]. The L variant was associated with a better response, while SS genotype was linked to lower rates of remission and longer response times. BD patients carrying the S allele were also more susceptible to developing anti-depressant-induced mania (AIM) with a 35% increase in risk [95].

**GRIK4**

The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study included an initial period of citalopram monotherapy. Of these SSRI-treated subjects, 1,816 were genotyped in a candidate gene study of 768 SNPs, identifying an association between the GRIK4 SNP rs1954787 and therapeutic response [96]. GRIK4 is a component of the ionotropic kainate/glutamate receptor. An attempt to replicate this finding in 387 BD/MDD subjects found supportive evidence for a GRIK4 association, but not at the same SNP, and required a gene x gene interaction [97].

**HTR2A**

Since the serotonin transporter is a direct target of SSRIs, modulation of serotonin transmission has long been thought a key mechanism of action. A number of serotonin receptors have been studied and, in the STAR*D sample, an analysis of 1,953 patients revealed a strong association between the intronic HTR2A SNP rs7997012 and treatment response [98]. In a synergistic manner, homozygous carriers of the protective alleles of both GRIK4 and HTR2A were 23% more likely to respond to citalopram than participants carrying neither of these alleles [96].

**FKBP5**

FKBP5 has been implicated in psychiatric disorders because of its role encoding a co-chaperone protein for the glucocorticoid receptor. It has been shown to affect the hypothalamic–pituitary–adrenal (HPA) [99,100] and modulate Akt activity [101], thereby altering numerous neuronal functions [102,103]. Variation in FKBP5 was first associated with antidepressant response in two independent

---

**Table 3 Genetic markers associated with antipsychotics outcomes**

| Drug/Phenotype | Gene | Marker | Subjects | Studies | Diagnosis | Phenotypic association | Level of evidence |
|----------------|------|--------|----------|---------|-----------|------------------------|--------------------|
| Antipsychotics | DRD2 | rs1799732 | 687 | 6* | Schizophrenia | Del-allele associated with poor response | 1 |
| HTR2A         |      | rs6311  | 315 | 2 | Schizophrenia | A-allele associated with good response | 2 |
| ANKK1         |      | rs1800497 | 1,256 | 6* | Schizophrenia | A2-allele associated with TD risk | 1 |
| HTR2C         |      | rs3813929 | 1,108 | 14* | Schizophrenia | C-allele associated with weight gain | 1 |
| MC4R          |      | rs489693 | 344 | 4 | Unspecified | AA genotype associated with weight gain | 2 |
|               |      | rs17782313 | 345 | 1 | Multiple | C-allele associated with weight gain | 2 |

*Includes meta-analyses. TD, tardive dyskinesia.
samples [104]. In a subsequent meta-analysis of eight studies including more than 2,199 patients, this association was replicated [105].

Genome-wide association studies

Because the results have been better replicated, most of the markers discussed above come from candidate gene studies. However, by surveying the entire genome, GWAS have the ability to identify previously unrecognized pharmacogenetic markers that could not be predicted based on candidate hypotheses. While some of these studies require replication or have failed to achieve genome-wide significance, several large GWAS of drug response have been conducted and are worthy of mention.

A GWAS of lithium response recently reported very strong evidence of association (P = 10^{-35}) for a variant in the gene glutamic acid decarboxylase like 1 (GADLI) in a sample of 294 Taiwanese subjects [106]. This result was then replicated in smaller samples of 100 and 24 subjects by the same investigators. This is an exciting result awaiting independent replication. A GWAS analysis of citalopram response in the STAR*D cohort yielded suggestive associations for markers in RORA, LBE3C and BMP7, but none that met genome-wide thresholds for significance [107]. A similar analysis revealed a number of suggestive associations of citalopram-induced side effects, most prominently a marker in EMID2, associated with altered vision and hearing [108]. More recently, data emerged from a meta-analysis of >2,200 MDD patients from the STAR*D, Genome-Based Therapeutic Drugs for Depression (GENDP) and Munich Antidepressant Response Signature (MARS) trials [109]. In this study, a number of suggestive markers were associated with various response indicators, but none met genome-wide thresholds for significance. Taking a different approach, GWAS analysis for copy number variation using the STAR*D sample and a health system repository revealed a modest enrichment of chromosomal duplications among treatment refractory depression cases, and a deletion in PABPCAL uniquely affecting treatment-resistant MDD patients, but was restricted to only a small number of subjects [110].

As with case–control studies of BD, MDD and SCZ, GWAS approaches have generally not supported previously reported candidate gene associations. While the reasons for this discrepancy are unclear, it does underscore the relative strengths and weaknesses of candidate gene studies and GWAS. Candidate gene studies are limited in scope, focusing on individual genes, while GWAS surveys the entire genome. Yet because of this focus, candidate gene studies often have greater statistical power with smaller sample sizes for any individual gene. Practically, however, these studies do not generally correct for the total number of SNPs examined in the same sample. The price of the wide scope of GWAS is the large number of statistical tests and the very large sample sizes required to achieve statistical significance. Such large sample sizes are particularly problematic for pharmacogenetics where the cost of assessing the phenotype, via a prospective clinical trial, is very high, and uniformity of treatment among subjects is rare. Future GWAS with larger samples will likely identify many new drug response loci. Until then, we argue that the strongest candidate gene markers likely provide valid, but incomplete, answers that warrant testing for utility.

Pharmacokinetics

**CYP450 enzymes**

Cytochrome P450 enzymes constitute a major component of the human drug metabolism system, activating/deactivating and facilitating the elimination of compounds [111,112]. Many drugs used to treat BD are eliminated by CYP450 enzymes, and knowledge of a patient’s CYP450 genotype can be invaluable in selecting medications or doses. While pharmacokinetics have been largely neglected in previous reviews of the pharmacogenetics of BD, CYP450 genotyping is now approaching mainstream use, with FDA approval of CYP450 testing for 27 alleles in CYP2D6 and three alleles in CYP2C19 [113,114]. CYP450 genotypes are highly variable, with numerous functionally distinct haplotypes, but are frequently organized by metabolic activity into different phenotypic categories. For example, 2D6 phenotypes are commonly classified as: poor metabolizers (PM) with completely absent enzymatic
activity; intermediate metabolizers (IM) with decreased enzymatic activity; extensive metabolizers (EM) with normal enzymatic activity; and ultra-rapid metabolizers (UM) with increased enzymatic activity [115]. The relative frequency of minor allelic variants differs greatly by ethnicity [116-118]. For example, among East Asians approximately 30% carry the null CYP2C19 haplotypes *2 and *3, that lead to a total absence of CYP2C19 activity. In contrast, the frequency in Caucasians ranges from 4% to 13% [119]. On the other hand, <5% of East Asians possesses the CYP2C19 *17 allele that increases activity, whereas the rate in Northern European Caucasians is 18% [120,121].

**CYP2D6**

CYP2D6 is involved in the metabolism of more than 70 drugs, including many anti-depressants and anti-psychotics. The CYP2D6 gene is located at 22q13.1, and encodes the CYP2D6 enzyme [122,123].

**CYP2D6 and antidepressants**

CYP2D6 genotype has been shown to be associated with antidepressant outcomes across several dimensions [124-126]. Response to venlafaxine was significantly greater in CYP2D6 EM subjects who metabolize the drug normally compared IM subjects who require lower doses [127]. MDD patients showed higher rates of remission among CYP2D6 IMs compared to PMs, after eight weeks of escitalopram treatment [128]. CYP2D6 UM status contributed to non-response by increasing early dropout rates [129,130], and CYP2D6 UM status was associated with a higher risk of suicide [131-133]. Finally, CYP2D6 genotype predicts the risk of adverse effects as shown among PMs treated with venlafaxine and tricyclic antidepressants (TCAs) [134,135]. Most dramatically, cases have been reported of PMs being linked to fatal responses to antidepressants [136,137]. While compelling evidence links functional CYP2D6 haplotypes to drug levels [138], other studies failed to determine an association between CYP2D6 polymorphisms and treatment response [139-141], leading the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) group to conclude that the evidence in support of CYP2D6 genotyping for guiding antidepressant treatment is inconclusive, and recommending implementation clinical trials in order to show the benefits from CYP2D6 genotype [142].

**CYP2D6 and antipsychotics**

CYP2D6 mediates the metabolism of many antipsychotics, making the use of genetic information about this locus a rational strategy for personalized medicine [143-146]. However, the utility of CYP2D6 genotyping in predicting clinical response to antipsychotics is relatively unexplored. CYP2D6 genotype did predict tolerability to risperidone with a higher risk of adverse effects among PMs [147,148].

**CYP2C19**

CYP2C19 is involved in the metabolism of a wide range of anti-depressants and benzodiazepines [149,150]. The CYP2C19 gene is located at 10q24.1-q24.3.

**CYP2C19 and antidepressants**

CYP2C19 has been shown to be the primary metabolic enzyme for citalopram, escitalopram, amitriptyline and clomipramine [115,151-153]. Functional CYP2C19 haplotypes have been associated with serum concentrations of citalopram [151,154] and escitalopram [138,155]. Analysis of the Caucasian subset of the STAR*D sample revealed an association between the inactive *2 allele and tolerance to citalopram [156].

**Other pharmacokinetic targets**

**ABCB1**

P-glycoprotein (P-gp), one of the ATP-binding cassette (ABC) transporter proteins, actively transports drugs, including antidepressants, across the blood–brain barrier [157,158]. Multiple SNPs in ABCB1, coding for P-gp, were associated with response to citalopram, paroxetine, amitriptyline and venlafaxine, substrates of P-gp [159]. Two of the latter were replicated in a geriatric sample receiving paroxetine [160] and associated with SSRI-related adverse effects in a separate study [161].

**Pharmacogenetics and clinical practice: are we there yet?**

Psychiatry lacks objective biological disease markers to guide diagnosis and treatment, creating a situation analogous to cardiologists relying on subjective descriptions of chest pain, without the aid of electrocardiograms, biochemical markers, or blood pressure cuffs to differentiate among syndromes or track recovery. While the discovery of predictive genetic markers is just beginning, evidence already exists for a number of well replicated PGT markers. This has raised a number of questions in the psychiatric literature [162], including: How strong must the supporting evidence be? How large is a clinically relevant effect? What degree of specificity and sensitivity are required? Does a given marker influence decision making and have clinical utility? In short, can the existing genetic data be translated from statistical associations to clinically informative tools? The answer remains unclear. A genetic marker can correlate with an outcome, but be deemed clinically useless because of low predictive value, poor specificity or limited external validity [163,164]. Some have argued against implementation [162-165], concluding that PGT markers are not yet sufficiently sensitive or specific [165]. However, the utility or lack of utility of PGT is an empirical question that has remained largely untested.
Pharmacogenetic implementation studies: design and execution

The gold standard for determining the utility of a therapeutic intervention is the randomized clinical trial. This method is readily applied to PGT by comparing the outcomes of PGT guided treatment against treatment as usual (TAU). Figure 1 illustrates a simple, two arm design that could test the clinical utility of PGT. Outcomes could be measured across a number of dimensions including response magnitude, time to response, symptom burden, side effect burden, disability and cost. In principle, improvement on even a single dimension could constitute a successful trial.

Designing the test panel

The design of PGT panels is likely to evolve rapidly. Costs for whole genome sequencing are falling rapidly, and it is expected that this technology will be widely available once the cost drops below $1,000 [166]. Therefore, in the near future, costs of whole genome sequencing will be comparable to other common medical tests, allowing for the patient’s entire genetic sequence and interpretation to be part of the electronic medical record. In the interim, candidate gene panels composed of a limited set of markers, targeting key biological functions offer a cost effective and technically plausible format for focused genotyping. For illustrative purposes, we have selected the well replicated markers described above to show how a candidate gene variant panel might be selected, configured and implemented.

Reporting and recording genetic results

Most psychiatrists lack training in advanced genetics and may have difficulty understanding PGT results. Therefore, in the design of a PGT, it is important to convey results in a simple manner that can be understood and quickly incorporated into clinical decision making without losing pertinent detail. To address the dilemma presented by these competing interests, a PGT report may require multiple layers, each coherent and internally consistent, that presents information with increasing levels of detail, starting with general drug recommendations and ending with the raw genotype results and technical details of the assay.

An algorithm for integrating genetic results

Frequently, a medication may have multiple, relevant genetic marker associations (for example, one for response, others for side effects), a genetic marker may be relevant to multiple medications, and different genetic markers may suggest opposite actions. Therefore, the PGT results for each variant need to be reconciled and consolidated into a single, overall recommendation. The process of synthesizing PGT results from multiple markers into coherent treatment recommendations for the physician may prove challenging. One solution to this challenge is to develop algorithms that prioritize and apply differential weight to potential clinical outcomes (Figure 2). We approached this by first classifying all relevant drug-marker combinations into four clinical recommendations: 1) use with caution; 2) potential limitations to use; 3) use as directed; and 4) preferred use. We then developed an algorithm (Figure 2), that generates an overall recommendation.

Figure 1 A pharmacogenetics implementation design. Patients are randomized to pharmacogenetic test (PGT) guided treatment or treatment as usual (TAU). For the PGT group, the physician incorporates the results of the test to make treatment decisions; in the TAU group, the physician treats according to usual practice based on evidence-based treatment guidelines. Subjects are assessed longitudinally and outcome compared after the specified treatment interval.
for each drug based on genotype. In this algorithm, drugs are serially considered in descending order of expected adverse events, starting with the most severe. For example, genotypes that predict high risk for life-threatening/serious adverse effects are considered first, thereby removing drugs that could present imminent danger to the subject (for example, HLA-B1502 and SJS). Medications are then considered with respect to genetic risk of long-term side effects and/or higher dosing requirements (for example, CYP450 UMs). Finally, drugs are assessed in terms of genetic associations with symptom response. The set of drugs with minimal side effect associations, but no information on response will be classified for ‘Use as directed’. Those with minimal/no side effect associations predicted to show a good response are classified for ‘Preferred use’. Given the common nature of many of the risk-associated markers that preclude ‘preferred’ status, this latter set of drugs will typically be small, (perhaps even nonexistent for patients with some genotypes), but optimally matched to an individual,

![Diagram](image_url)
narrowing the available choices for making ‘the best decision’, and eliminating choices that are less likely to work or to be poorly tolerated. Importantly, the algorithm does not replace clinical judgment, and the physician is free to incorporate relevant information from other sources (for example, clinical features, drug-drug interactions) to weigh options alternatively, or, when indicated, to override the algorithm.

Special considerations in clinical trial design
There are several factors that differ between a PGT implementation study and a randomized clinical trial (for example, for a medication) or genetic association study that warrant special consideration. First, in designing an implementation study, a panel of genetic markers is evaluated, not a single genetic marker, and the efficacy of the panel as a whole is tested. Not all markers will be relevant to a given patient or decision, but the breadth of multi-marker panels affords the clinician an opportunity to survey several low frequency alleles with good efficiency, offering broad utility in a naturalistic environment. This approach does have limited ability to test the benefit of any single genetic association included in the panel. It is assumed that not every result will support a previously established genetic association, but that in aggregate, treatment outcomes will be improved based on the PGT results. Over time, data can be collected regarding clinician choices and specific markers. In this manner, insight into which components of the test are most useful can be developed.

In an implementation study, the effectiveness of treatment, regardless of the specific drug(s) used is the most important variable. The hypothesis is that outcomes in PGT are superior to TAU as a result of genetic information being conveyed to the physician, not that a specific drug is better. Appropriate clinical use of PGT data will differ among clinicians, and this variability must be controlled. The use of evidence-supported clinical treatment guidelines can standardize some practices. However, ‘real world patients’, particularly those with treatment refractory symptoms, often have extensive treatment histories that can make it difficult to fit them into standardized algorithms. To mitigate this difficulty, experimental blinding is essential. Since the physician is required to interpret genetic data and make decisions based upon the results, the physician cannot be blinded. However, by obtaining DNA on all subjects, patients can be blinded if their data are withheld. Independent raters can also be blinded to assess outcomes. Many other clinical trial designs are possible, and their respective strengths and weaknesses have been recently reviewed [162].

Early implementation studies
Using a panel of five genetic markers and a design similar to the one outlined above, a PGT implementation study of 44 MDD patients was completed using a commercially available test, yielding promising results [167]. Treatment refractory patients with MDD were divided into PGT and TAU groups. Depressive symptoms were significantly decreased in the PGT group compared to TAU, as shown by greater reductions in QIDS-C16 and HAM-D17 scores at the eighth week. More recently, similar differences were shown by the same group using a larger replication sample of 227 MDD patients [168]. The same test was retrospectively applied to 97 subjects for whom health insurance records were available. In this way, genetic testing predicted healthcare utilization and costs. When patients were prescribed medications later found to be poorly matched to genotype, they required more frequent visits, took more medication and required greater expenditures [169]. In all three of these reports, differences in outcome were driven primarily by the genotypes expected to have the most severe outcomes, primarily those expected to metabolize medications poorly, resulting in more adverse effects. Strikingly, these most severe mismatches were commonly encountered, affecting approximately 25% of the subjects in one study [168]. Several limitations in these studies warrant mention. First, both efficacy trials were open label and not randomized, meaning that patients were aware of their group assignment. Second, the samples were small, ethnically homogenous and collected from single sites, potentially limiting the external validity of the results. Nonetheless, the improvement over TAU is particularly striking given the nature of the subjects, many of whom suffered from chronic refractory depression. To date, no trials in BD have been conducted.

Summary
Statistically significant, but clinically significant?
The findings summarized indicate that a number of PGT markers are reliably associated with clinically salient treatment outcomes. Although this is a very early stage in the discovery of PGT markers in BD, this set of genes is expected to be refined and enlarged over time, and we argue that there are already enough potentially informative results to warrant implementation studies to determine their clinical utility.

Whether or not the pharmacogenetic panel presented here can be used to improve outcomes in clinical practice is an untested question. In clinical trials, the concepts of effect size, sensitivity (labeling a true positive as positive) and specificity (labeling a true negative as negative) are used to measure the value of a biological test. Psychiatric PGT has been criticized for individual allelic associations falling short on these measures. However, three counterpoints can be offered. First, PGT implementation takes advantage of multiple genetic markers, and while individual markers may be non-specific, limited in applicability, or yield small effects, a more comprehensive panel, utilizing
multiple markers may prove to be more robust. Second, in the absence of objective markers to guide decisions, medication choice in BD is presently made in a largely trial and error fashion. In this case, even small improvements in care could represent a significant advance. Third, the interactions among genetic variants, medications and individual patients are sufficiently complex that a priori estimates of sensitivity and specificity may not accurately predict the outcome of a PGT trial. Only empirical data can determine the value of PGTs in clinical practice. Hence, we conclude that the potential for benefit from PGT is high, and will only increase as whole genome sequence information becomes widely incorporated into newer PGT panels and new genetic associations are discovered.

On the other side of the equation, the costs of repeated medication trials, prolonged illness, clinician time and unanticipated adverse drug events are also high, while the cost of genotyping, incurred only once, is relatively low, and likely to drop further. Therefore, while the potential for therapeutic gains may be modest in the first iterations of an PGT, the downside risk imposed upon the patient is minimal, making the cost-benefit ratio strongly favorable. Therefore, carefully designed implementation studies constitute an essential and effective tool in addressing these concerns while playing an instrumental role in the validation process of genetic tests and their introduction into routine psychiatrist practice. Implementation studies, as proposed here, will likely be a useful approach in deciding the value of a genetic test in real world clinical situations [162].

Abbreviations

ABCC1: gene for an ATP binding cassette transporter protein; AIMP: antidepressant-induced mania; ANKK1: ankyrin repeat and kinase domain containing 1; BD: bipolar disorder; BDNF: brain-derived neurotrophic factor; bp: base pair; CBZ: carbamazepine; CREB: cyclic AMP response element; CYP450: family of proteins involved in drug metabolism; DRD2: gene for the D2 dopamine receptor; epS: extrapyramidal symptoms; FKBP5: gene for a co-chaperone protein for the glucocorticoid receptor; GRIA2: AMPA type glutamate receptor subunit; GRK4: gene for the ionotropic kainate glutamate receptor; GSK3B: glycogen synthase kinase beta; GWAS: genomewide association study; HTR2A: gene for the serotonin 2A receptor; HTR2C: gene for the serotonin 2C receptor; MC4R: gene for the melanocortin 4 receptor; MDD: major depressive disorder; NTRK2: gene name for the TrkB receptor; ODZ4: gene for Odd Oz/Ten-m Homolog 4; PGx: pharmacogenomic guided treatment; SCH: schizophrenia; SJS: Stevens-Johnson syndrome; SLC6A4: gene for the serotonin transporter; SNP: single nucleotide polymorphism; SSR: selective serotonin reuptake inhibitor; TAU: treatment as usual; TrkB: tropomyosin related kinase B.

Competing interests

The authors declare they have no competing interests.

Authors’ contributions

NS conducted literature searches and wrote portions of the manuscript; MM was involved in conceptualization of the paper and wrote portions of the manuscript; SL conducted literature searches and helped draft the manuscript; JK helped in conceiving the paper and wrote portions of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This research was supported by grants from the Department of Veterans Affairs Office of Research and Development to MUM (IK2BX001275) and JKR (I01CX003063). Support was also provided to JKR by the NIIMH, the Pharmacogenomics Research Network (MH094483 and MH092758) and the Brain Behavior Research Foundation. Support was also provided by the NIH funded UCSD Clinical Translational Research Institute (UL1TR000100). The funders had no role in the analysis, decision to publish, or preparation of the manuscript.

Author details

1Department of Psychiatry (0603), University of California San Diego, La Jolla, CA 92039, USA. 2VA San Diego Healthcare System, 3350 La Jolla Village Drive, La Jolla, CA 92151, USA. 3Institute for Genomic Medicine, University of California San Diego, La Jolla, CA 92039, USA.

Received: 13 November 2013 Accepted: 29 April 2014
Published: 30 May 2014

References

1. Kesler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:593–602.
2. Begley CE, Annegers JF, Swann AC, Lewis C, Coan S, Schnapp WB, Bryant-Comstock L: The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoecon 2001, 19:483–495.
3. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beau lieu S, O’Donovan M, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Young AH, Aida M, Miley R, Viera E, Calabrese JR, Berk M, Ha K, Kapczinski F: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder; update 2009. Bipolar Disord 2009, 11:225–255.
4. Suppes T, Dennehy EB, Hirschfeld RM, Althuler LL, Bowden CL, Calabrese JR, Crinnon ML, Ketter TA, Sachs GS, Swann AC: The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar disorder. J Clin Psychiatry 2005, 66:780–886.
5. Hirschfeld RM, Lewis L, Vornik LA: Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association survey 2000 of individuals with bipolar disorder. J Clin Psychiatry 2003, 64:161–174.
6. Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, Masangil LB, Mikkowitz DJ, Miyahara S, Bauer MS, Thase ME, Wisniewski SR, Sachs GS: Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, mirtazapine, or risperidone. Am J Psychiatry 2006, 163:210–219.
7. Ritchie MD: The success of pharmacogenomics in moving genetic association studies from bench to bedside: study design and implementation of precision medicine in the past GWAS era. Hum Genet 2012, 131:1615–1626.
8. Johnson JA, Gong L, Whiff-Carrillo M, Gage BF, Stein CM, Anderson JL, Kimmel SE, Lee MT, Pirmohamed M, Wadelius M, Klein TE, Altman RB, Clinical Pharmacogenetics Implementation Consortium: Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011, 90:252–629.
9. van den Akker-van Marle ME, Gurwitz D, Detmar SB, Enzing CM, Hopkins MM, Gutierrez De Mesa E, Ibarreta D: Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopeurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 2006, 7:765–792.
10. Schaeffler E, Fischer C, Brockmeier D, Wernet D, Moerike O, Kichelbaum M, Zanger UM, Schwab M: Comprehensive analysis of thiopeurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel PMT variants. Pharmacogenomics 2004, 14:407–417.
11. Doris MA, Sullivan S, Phillips E, Carson G, Molina JM, Wofkan C, Tomasz J, Jagel-Guedes E, Rugina S, Kopyrow O, Cid JJ, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A, PREDICT-1 Study Team: HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008, 358:568–579.
12. Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz DL: Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther 2012, 91:734–738.
13. Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE: Pharmacogenomics and individualized medicine: translating science into practice. *Clin Pharmacol Ther* 2012, 92:467–475.

14. McCarth MJ, Leckband SG, Kelsey JR: Pharmacogenetics of lithium response in bipolar disorder. *Pharmacogenomics* 2010, 11:1439–1465.

15. Rybakowski JK: Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge. *CNS Drugs* 2013, 27:165–173.

16. Klein TE, Altman RB: PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base. *Pharmacogenomics* 2004, 4:1.

17. Tondo L, Hennen J, Baldessarini RJ: Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. *Acta Psychiatr Scand* 2001, 104:163–172.

18. Smith LA, Cornelius V, Warnock A, Bell A, Young AH: Effectiveness of mood stabilizers and antidepressants in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. *Bipolar Disord* 2007, 9:394–412.

19. Kessing LV, Hellmund G, Andersen PK: Predictors of excellent response to lithium: results from a nationwide register-based study. *Int Clin Psychopharmacol* 2011, 26:323–328.

20. Smith DJ, Evans R, Caddick N: Predicting response to lithium in bipolar disorder: a critical review of pharmacogenetic studies. *J Ment Health* 2010, 19:142–156.

21. Grof P: Selecting effective long-term treatment for bipolar patients: monotherapy and combinations. *J Clin Psychiatry* 2003, 64:53–61.

22. Berghoff A, Alda M, Adli M, Baethge C, Bauer M, Bischot T, Glenn T, Grof P, Muller-Oerlinghausen B, Repa S, Rybakowski J, Suwalska A, Pfennig A: Long-term effectiveness of lithium in bipolar disorder: a multicenter investigation of patients with typical and atypical features. *J Clin Psychiatry* 2008, 69:1860–1868.

23. Lewin GR, Barde YA: Physiology of the neurotrophins. *Annu Rev Neurosci* 1996, 19:289–317.

24. Aczkely F, Koltay M, Olofsson K, Opgen R, Linderwall O: Affinent-specific modulation of short-term synaptic plasticity by neurotrophins in dentate gyrus. *Eur J Neurosci* 2000, 12:663–669.

25. Alzina B, Yu T, Cohen-Cory S: Visualizing synaptic formation in arborizing optic axons in vivo: dynamics and modulation by BDNF. *Nat Neurosci* 2004, 1:1093–1101.

26. Shaltiel G, Chen G, Manji HK: Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. *Curr Opin Pharmacol* 2007, 7:22–33.

27. Tseng M, Alda M, Xu L, Sun X, Wang JF, Grof P, Turecki G, Rouleau G, Young LT: BDNF protein levels are decreased in transformed lymphoblasts from lithium-responsive patients with bipolar disorder. *J Psychiatry Neurosci* 2008, 33:449–453.

28. Hashimoto R, Takei N, Shinmizu K, Christ L, Lu B, Chuang DM: Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. *Neuropharmacology* 2002, 43:1173–1179.

29. Sklar P, Gabriel SB, McInnis MG, Bennett P, Lim YM, Tian G, Schaffner S, Kirov G, Jones I, Owen M, Craddock N, DePaulo JR, Landi ES: Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neurotrophic factor. *Mol Psychiatry* 2002, 7:579–593.

30. Sears C, Marke D, Olds R: Fitches A: Evidence of associations between bipolar disorder and the brain-derived neurotrophic factor (BDNF) gene. *Bipolar Disord* 2011, 13:630–637.

31. Kremen B, Herzberg I, Garcia J, Kerr E, Duque C, Parra V, Vega J, Lopez C, Vernet C, Garcia J, Muller-Oerlinghausen B, Rybakowski J, Suwalska A, Pfennig A, Herold C: Pharmacogenomic and pharmacogenetic studies of the BDNF Val66Met polymorphism in major affective illness: a meta-analysis. *Acta Psychiatr Scand* 2010, 121:630–637.

32. Kremeyer B, Herzberg I, Garcia J, Kerr E, Duque C, Parra V, Vega J, Lopez C, Vernet C, Garcia J, Muller-Oerlinghausen B, Rybakowski J, Suwalska A, Pfennig A, Herold C: Pharmacogenomic and pharmacogenetic studies of the BDNF Val66Met polymorphism in major affective illness: a meta-analysis. *Acta Psychiatr Scand* 2010, 121:630–637.

33. Kremen B, Herzberg I, Garcia J, Kerr E, Duque C, Parra V, Vega J, Lopez C, Vernet C, Garcia J, Muller-Oerlinghausen B, Rybakowski J, Suwalska A, Pfennig A, Herold C: Pharmacogenomic and pharmacogenetic studies of the BDNF Val66Met polymorphism in major affective illness: a meta-analysis. *Acta Psychiatr Scand* 2010, 121:630–637.

34. Wang Z, Lu Z, Chen J, Huang J, Yuan C, Hong W, Yu S, Fang Y: Association of genetic variants in the CREB family of genes. *Mol Psychiatry* 2011, 16:198–213.
52. Klein PS, Melton DA: A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 1996, 93:8455-8459.

53. Gould TD, Chen G, Manji HK: In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 2004, 29:32-38.

54. Benedetti F, Serretti A, Pontiggia A, Beranovicu A, Lorenzi C, Calombo C, Cereda E: Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta –50 T/C SNP. Neurosci Lett 2005, 376:51-55.

55. Lin YF, Huang MC, Liu HC: Glycogen synthase kinase 3beta gene polymorphisms may be associated with bipolar I disorder and the therapeutic response to lithium. J Affect Disord 2012, 147:401-406.

56. Adli M, Hollinde DL, Stamn T, Wetheroff K, Tshaharud K, Kircheiner H, Heinz A, Bauer M: Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50 T/C single nucleotide polymorphism. Biol Psychiatry 2007, 62:1295-1302.

57. Michelon L, Meira-Lima I, Cordeiro Q, Miguita K, Breen G, Collier D, Vallada H: Association study of the INPP1, SHTT, BDNF, AP-2beta and GSK-3beta GENE variants and retrospectively scored response to lithium prophylaxis in bipolar disorder. Neurosci Lett 2005, 403:288-293.

58. Szczepankiewicz A, Rybakowski JK, Suwalska A, Skibinska M, Leszczynska-Rodziewicz A, Dmietrak-Weglasz C, Czerski PM, Hauser J: Association study of the glycogen synthase kinase 3-beta gene polymorphism with prophylactic lithium response in bipolar patients. World J Biol Psychiatry 2006, 7:151-156.

59. Ballenger JC, Post RM: New trends in the treatment of bipolar disorder. J Clin Psychiatry 2007, 68:278-280.

60. Weisler RH, Keck PE Jr, Swann AC, Cutler AJ, Ketter TA, Kalali AH: Antipsychotic drug treatment: principles and practice. CNS Drugs 2007, 21:47-71.

61. Post RM, Ketter TA, Uhde T, Ballenger JC: Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta –50 T/C SNP.

62. Klein PS, Melton DA: In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 2004, 29:32-38.

63. Arranz MJ, Munro J, Owen MJ, Spurlock G, Sham PC, Zhao J, Kirov G, Collier DA, Kenin RW: Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry 1998, 3:61-66.

64. Turecki G, Briere R, Dewar K, Antonette T, Lesage AD, Seguin M, Chavly N, Vanier C, Alida J, Boobier K, Renflect C, Rouleau GA: Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am J Psychiatry 1999, 156:1453-1458.

65. De Luca V, Mueller DJ, de Bartolomeis A, Kennedy JL: The hardness of obesity: a soft-wired hypothalamus. J Clin Endocrinol Metab 2008, 93:718-720.

66. Malhi GS, Tanious M, Berk M: Mania: diagnosis and treatment recommendations. Curr Psychiatry Rep 2012, 14:676-686.

67. Sanford M, Keating GM: Quetiapine: a review of its use in the management of bipolar depression. CNS Drugs 2012, 26:435-460.

68. Lieberman JA, Stroup TS, McEvoy JP, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am J Psychiatry 1999, 156:1453-1458.

69. De Luca V, Mueller DJ, de Bartolomeis A, Kennedy JL: Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int J Neuropsychopharmacol 2007, 10:979-704.

70. Lois RJ, Lindgren CM, Li S, Wheeler E, Zhao JH, Prokopenko I, Ioannou Y, Manoli AM, Trathnigg PW, Richmond D, Li X, Chen W, Li S, Zhao Z, Prokopenko I, Ioannou Y, Manoli AM, Trathnigg PW, Richmond D, Li X, Chen W, Li S, Zhao Z: Common variant at 16p11.2 common variant near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet 2008, 40:768-775.

71. Chambers JC, Elliott P, Zabaneh D, Zhang W, Li Y, Frooguel P, Balding D, Scott J, Jonker CS: Common genetic variation near MC4R is associated with waist circumference and insulin resistance. Nat Genet 2009, 41:716-718.

72. Mountjoy KG, Morritt MT, Low MJ, Sirley RB, Cone RD: Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol 1994, 8:1298-1308.

73. Horvath TL: The hardship of obesity: a soft-wired hypothalamus. Nat Neurosci 2005, 8561-565.

74. Malhotra AK, Cornell CI, Chowdhury N, Muller DJ, Gregersen PK, Lee AT, Tiwari AK, James KD, Fleischacker WW, Kahn R, Ophoder FA, Metzler HY, Lenz T, Kennedy JL: Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry 2012, 69:904-912.

75. Czernik F, Leucht S, Steimer W: Association of the common MC4R r17782313 polymorphism with antipsychotic-related weight gain. J Clin Psychopharmacol 2013, 33:74-79.

76. Sachs GS, Nierenberg AA, Calabrese JR, Manberg LB, Wisniewski SR, Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher MJ, Patel J, Hauser P, Rapport D, Martinez JM, Allen MH, Miklowitz DJ, Otto MW, Dennehy BT, Thase ME: Effectiveness of adjunctive antidepressant treatment for bipolar depression. Am J Psychiatry 2005, 162:1711-1722.

77. Brown EB, McElroy SL, Keck PE Jr, Deldar A, Adams DH, Tohen M, Williamson D: A 7-week, randomized, double-blind trial of olanzapine/ fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006, 67:1025-1033.

78. McElroy SL, Weisler RH, Chang W, Glaubson B, Paulson B, Brecher M, Agababian V, Merideth C, Nordenheim A, Young AH: A double-blind,
placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010, 71:163–174.

92. Hells A, Teufel A, Petri S, Stober G, Riedereer P, Bengel D, Lesch KP: Allelic variation of human serotonin transporter gene expression. J Neurochem 1996, 66:262–265.

93. Philbert EA, Sandhu H, Hollenbeck N, Gunter T, Adams W, Madan A: The relationship of SHMT (SLC6A4) methylation and genotype on mRNA expression and liability to major depression and alcohol dependence in subjects from the Iowa Adoption Studies. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:543–549.

94. Serretti A, Kato M, De Ronchi D, Kinoshita T: Neurobiology of antidepressant treatment. J Clin Psychiatry 2010, 71:1188–1196.

95. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, Sorant AJ, Salloum M: Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994, 46:452–459.

96. Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Salloum M, Bennington JD, Gainetdinov RR, Caron MG: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006, 7:506–619.

97. Beaulieu JM, Gainetdinov RR, Caron MG: The pharmacogenetics of antidepressant resistance: a systematic review and meta-analysis. Bipolar Disord 2010, 12:102–106.

98. Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Salloum M, Bennington JD, Gainetdinov RR, Caron MG: The pharmacogenetics of antidepressant treatment. Nat Rev Neurosci 2010, 11:527–540.

99. McMahon FJ, Buenovich S, Charney D, Lipsky R, Rush AJ, Wilson AF, Sorant AJ, Papanicolaou GJ, Laje G, Fava M, Trivedi MH, Winisnik SM, Manji H: Variation in the gene encoding the 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006, 78:894–894.

100. Denny WB, Valentine DL, Reynolds PD, Smith DF, Scammell TG: Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding. Endocrinology 2002, 143:101–113.

101. Holsoe F: The rationale for corticoprotein-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 1999, 33:181–214.

102. Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, Petersen G, Lou Z, Wang L: FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 2009, 16:259–269.

103. Engelman JA, Luo J, Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2005, 6:750–619.

104. Zou YF, Wang F, Feng XL, Li WP, Tao JH, Pan FM, Huang F, Su H: Meta-analysis of FKBP5 genes polymorphisms association with treatment response in patients with mood disorders. Neurosci Lett 2010, 484:56–61.

105. Chen CH, Lee CS, Lee MT, Ouyang WC, Chen CC, Chong MY, Wu JY, Tan HK, Kohane IS, Churchill SE, Castro VM, Clements CC, Blumenthal SR, Murphy SM, Smoller JW, Perlis RH: Rare copy number variation in treatment-resistant major depressive disorder. Biol Psychiatry 2014. doi:10.1016/j.biopsych.2013.10.028.

106. Guengerich FP: Cytochrome p450 and chemical toxicology. Chem Res Toxicol 2008, 21:770–2784.

107. Groves JT, McCusky GA: Aliphatic hydroxylation by highly purified liver microsomal cytochrome P-450, Evidence for a carbon radical intermediate. Biochem Biophys Res Commun 1978, 118:154–160.

108. de Leon J: AmpliChip CYP450 test: personalized medicine has arrived in psychiatry. Expert Rev Mol Diagn 2008, 8:277–286.

109. de Leon J, Susce MT, Murray-Garcillan E: The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol Diag Ther 2006, 10:135–151.

110. Kirchheiner J, Nickenich K, Bauer M, Wong ML, Licinio J, Roots I, Brockmoller J: Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variation to the phenotype of drug response. Mol Psychiatry 2004, 9:442–473.

111. Johansson J, Ocason M, Yue QY, Bertilsson L, Sjoqvist F, Ingelmann-Sundberg M: Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994, 46:452–459.

112. Ingelmann-Sundberg M: Genetic polymorphisms of cytochrome p450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics 2005, 5:5–13.

113. Wu A, Kneller BM, Retie AE, Haining R: Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D1, 2D6, 2D10, and 2D17 allelic isoforms. J Pharmacol Exp Ther 2002, 303:1291–1300.

114. Man M, Farmen M, Dumaual C, Teng CH, Moser B, Irie S, Noh GJ, Niau R, Close S, Wise S, Hockett R: Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol 2010, 50:929–940.

115. Sim SC, Risinger C, Dahl ML, Akilli E, Christensen M, Bertilsson L, Ingelmann-Sundberg M: A common novel CYP2C19 gene variant causes ultrapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006, 79:103–113.

116. Ramsjo M, Akilli E, Bohman L, Ingelmann-Sundberg M, Reh HK, Bertilsson L, CYP2C19 activity competition between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. Eur J Clin Pharmacol 2010, 66:871–877.

117. Gonzalez FJ, Vilbois F, Hardwick JP, McBride OW, Nebert DW, Gelboin HV, Meyer UA: Human debrisoquine 4-hydroxylase (P450IID1): CDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. Genomics 1987, 1:217–179.

118. Kroemer HK, Eichelbaum M: “It’s the genes, stupid”. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995, 56:2285–2298.

119. Kootstra-Ros JE, Van Weelien MJ, Hinrichs JW, De Smet PA, van der Weide T: Therapeutic drug monitoring of antidepressants and cytochrome p450 genotyping in general practice. J Clin Pharmacol 2006, 46:1320–1327.

120. Richheimer J, Breslin K, Dahl ML, Gram LF, Kasper S, Roots I, Sjoqvist F, Spina E, Brockmoller J: CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subgroup-specific dosages. Acta Psychiatr Scand 2001, 104:173–192.

121. de Leon J, Armstrong SC, Cozza KL: Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006, 47:75–85.

122. Lobello KW, Preskorn SH, Guico-Pabia CJ, Jiang Q, Paul J, Nichols AI, Patroneva O, et al: AmpliChip CYP450 test: specificity and clinical utility. Mol Diag Ther 2006, 10:482–490.

123. Kroemer HK, Eichelbaum M: “It’s the genes, stupid”. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995, 56:2285–2298.
130. Penas-Ledo EM, Tejo HD, Dorado P, Ortega A, Jung H, Alonso E, Naranjo ME, Lopez-Lopez M, Larena A: CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients. Mol Psychiatry 2013, 18:8–9.

131. Penas-Ledo EM, Dorado P, Aguero Z, Gratasco M, Estibl X, Fernandez-Aranda F, Larena A: High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders. Mol Psychiatry 2013, 16:491–492.

132. Stingl JC, Viviani R: CYP2D6 in the brain: impact on suicidality. Clin Pharmacol Ther 2011, 89:352–353.

133. Zackrisson AL, Lindblom B, Ahlner J: High frequency of occurrence of CYP2D6 gene duplication/multiplication indicating ultrarapid metabolism among suicide cases. Clin Pharmacol Ther 2010, 88:354–359.

134. Lessard E, Yessine MA, Hamelin SA, O'Hara G, LeBlanc J, Turgeon J: Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant venlafaxine in humans. Pharmacogenet 1999, 9:435–443.

135. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A: Genetic variability of human liver cytochromes P450: CYP2D6 and ABCB1 polymorphism: influence on paroxetine drug reactions and discontinuation. J Clin Pharmacol 2000, 40:1;11–122.

136. Sallee FR, DeVane CL, Ferrell RE: Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group: Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic geriatric depression. J Clin Pharmacol 2008, 48:250–256.

137. Koski A, Ojpanera I, Sirjonen J, Vuori E, Sajantila A: A fatal doxepin poisoning associated with a defective CYP2D6 genotype. Ann Forensic Med Pathol 2007, 28:259–261.

138. Hodgson K, Tansley K, Demovicz MZ, Hauser J, Heningsgberg N, Maier W, Mors O, Placentino A, Retsch M, Sourey D, Smith R, Craig IV, Farmer AE, Atkinson QJ, Belsy S, Davis OS, Uher R, Mcguillin P: Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. J Psychopharmacol 2014, 28:133–141.

139. Serretti A, Calati R, Massar I, Linette S, Kasper S, Leucrifier Y, Sens-Espel R, Bollen J, Zohar J, Berlo J, Lienard P, De Ronchi D, Mendlewicz J, Souery D. Cytochrome P450 CYPIA2, CYPC9, CYPC29 and CYPD6 genes are not associated with response and remission in a sample of depressive patients. Int Clin Psychopharmacol 2009, 24:250–256.

140. Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry JM, Bondolfi G, Bertschy B, Stingl JC, Viviani R: CYP2D6 in the brain: impact on suicidality. Clin Pharmacol Ther 2011, 89:352–353.

141. Mehrez T, Drouin N, Bouchard V, Salle D: Pharmacogenetic factors associated with suicide in antidepressant-treated patients with major depression. Int J Neuropsychopharmacol 2007, 10:175–184.

142. Dorado P, Aguero Z, Gratasco M, Estibl X, Fernandez-Aranda F, Larena A: High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders. Mol Psychiatry 2013, 16:491–492.

143. Stingl JC, Viviani R: CYP2D6 in the brain: impact on suicidality. Clin Pharmacol Ther 2011, 89:352–353.

144. Lessard E, Yessine MA, Hamelin SA, O’Hara G, LeBlanc J, Turgeon J: Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant venlafaxine in humans. Pharmacogenet 1999, 9:435–443.

145. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A: Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002, 53:111–122.

146. Sallee FR, DeVane CL, Ferrell RE: Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group: Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic geriatric depression. J Clin Pharmacol 2008, 48:250–256.

147. Hodgson K, Tansley K, Demovicz MZ, Hauser J, Heningsgberg N, Maier W, Mors O, Placentino A, Retsch M, Sourey D, Smith R, Craig IV, Farmer AE, Atkinson QJ, Belsy S, Davis OS, Uher R, Mcguillin P: Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. J Psychopharmacol 2014, 28:133–141.

148. Serretti A, Calati R, Massar I, Linette S, Kasper S, Leucrifier Y, Sens-Espel R, Bollen J, Zohar J, Berlo J, Lienard P, De Ronchi D, Mendlewicz J, Souery D. Cytochrome P450 CYPIA2, CYPC9, CYPC29 and CYPD6 genes are not associated with response and remission in a sample of depressive patients. Int Clin Psychopharmacol 2009, 24:250–256.

149. Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry JM, Bondolfi G, Bertschy B, Stingl JC, Viviani R: CYP2D6 in the brain: impact on suicidality. Clin Pharmacol Ther 2011, 89:352–353.

150. Mehrez T, Drouin N, Bouchard V, Salle D: Pharmacogenetic factors associated with suicide in antidepressant-treated patients with major depression. Int J Neuropsychopharmacol 2007, 10:175–184.

151. Herlin K, Yasui-Furukori N, Tybring G, Widen J, Gustafsson LL, Bertilsson L: Metabolism of citalopram enantiomers in CYP2C9/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol 2003, 56:415–421.